Dr. Hanlan Liu has broad experience and a deep understanding of pharmaceutical R&D process based on more than 20 years of nonclinical research and development responsibilities in large pharma and biotech organizations. Hanlan has served as CSO & CDO of Sperogenix. Prior to join Sperogenix, she was the Vice President of Nonclinical Development at KSQ Therapeutics, where she co-led KSQ's 2 leading assets including KSQ-4279, a novel USP1 inhibitor, for the treatment of BRCA-deficient cancers currently in nonclinical development toward IND, and anti-NKG2A monoclonal antibody as immune-oncology combination therapy currently toward candidate selection stage. Before KSQ Therapeutics, Hanlan was Executive Director and Head of DMPK and Clinical Pharmacology at Catabasis Pharmaceuticals where she led clinical pharmacology strategy and work plan development for edasalonexent, an NF-kappa B inhibitor moving into Phase 3 clinical trial for Duchenne Muscular Dystrophy, as well as execution of DMPK strategy and the work plan for IND filing of CAT-5571, a potential novel therapy for the treatment of patients with cystic fibrosis. Before Catabasis, Hanlan spent 14 years at Genzyme and then Sanofi with increasing responsibilities and ultimately promoted to Senior Director in DMPK. During her tenure at Genzyme and Sanofi, Hanlan built and led multiple collaborative and science-driven pharmaceutics function groups associated with more than 30 drug discovery projects in multiple disease areas, several of which advanced to clinical trials. She contributed to 6 INDs and several product submissions and/or post market drug life cycle dossiers including those for Clofarabin®, Hectorol®, Mozobil®, Mipomerson® and Cerdelga®. Hanlan began her career in Ostuka in analytical and formulation and then Wyeth-Ayerst Research in early drug discovery. Between 2018 and 2020, Hanlan was the chair of New England Drug Metabolism Discussion Group steering committee. Hanlan earned her PhD of Analytical Medicinal Chemistry and Molecular Pharmacology and conducted postdoctoral work at Purdue University prior to completing her MBA in Corporate Finance with distinction at Stern Business School, New York University. Hanlan graduated with a BS in Biochemistry with honor at Wuhan University. Hanlan is the co-inventor on 7 patents including C.O.M. for Cerdelga® and venglustat and co-author of 34 peer-reviewed scientific publications.
address: A-216, No.56 Dongzhimen Wai Xie St. Chaoyang, Beijing 100027, China
tel: +86 10 6462 0528
address: Room 1502, Building C Poly West Bund Center, No.275, Ruiping Rd, Xuhui Disrict, Shanghai 200232, China